Sunshine Biopharma Inc. - SBFM STOCK NEWS

Sunshine Biopharma (NASDAQ: SBFM, SBFMW) announced an agreement to provide additional resources to the University of Arizona R. Ken Coit College of Pharmacy to expedite the development of PLpro inhibitors. This initiative includes the ongoing development of SBFM-PL4, aimed at combating SARS-CoV-2. Led by Dr. Gregory Thatcher, the research focuses on safety and efficacy testing against new Omicron variants. Sunshine Biopharma is also advancing its anticancer compound Adva-27a, targeting multidrug-resistant cancers in clinical trials set at McGill University.

Sunshine Biopharma, focused on oncology and antiviral drug development, announced the closing of a private placement raising approximately $19.5 million on April 28, 2022. The company issued 4,862,845 units at $4.01 each, which include shares and warrants exercisable at $3.76 each for a total of 9,725,690 shares. The funds will support ongoing research, including treatments for COVID-19 and drug Adva-27a, targeting multidrug-resistant cancer cells. The company plans clinical trials in Canada and is collaborating with the University of Arizona on additional drug research.

Sunshine Biopharma Inc. (NASDAQ:SBFM) has successfully completed a $19.5 million private placement, with Aegis Capital Corp. serving as the exclusive placement agent. This financing will support the advancement of its lead compound, SBFM-PL4, targeting COVID-19, and Adva-27a, an anticancer drug effective against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned in collaboration with McGill University. The company holds all patents related to Adva-27a, highlighting its strong position in developing innovative therapeutics.

Sunshine Biopharma has entered into a securities purchase agreement for approximately $19.5 million in gross proceeds. The offering involves issuing 4,862,845 units at a price of $4.01 per unit, which includes shares and warrants. The exercise of warrants could lead to 9,725,690 additional shares. The transaction, expected to close around April 28, 2022, is facilitated by Aegis Capital Corp. Sunshine Biopharma is also working on treatments for COVID-19 and developing the anticancer compound Adva-27a, targeting several resistant cancer types.

Sunshine Biopharma (SBFM, SBFMW) has filed a provisional patent application in the U.S. for mRNA molecules shown to effectively target cancer cells in pre-clinical trials. The mRNA demonstrated minimal toxicity to normal human cells while exhibiting cytotoxicity against various cancer types, including multidrug resistant breast and pancreatic cancer. Additionally, the company is enhancing its COVID-19 treatment research, having synthesized potential inhibitors and secured a collaboration with the University of Arizona. Clinical trials for its anticancer compound Adva-27a are planned at a Montreal hospital.

Sunshine Biopharma (NASDAQ: SBFM, SBFMW) announced promising results from tests on new mRNA molecules designed to combat cancer. These molecules effectively destroyed cancer cells including multidrug resistant breast cancer and pancreatic cancer cells, while showing minimal toxicity to normal human cells. The company plans to file a patent application soon. Additionally, Sunshine Biopharma is developing treatments for COVID-19 and Adva-27a, an anticancer drug aimed at multidrug resistant cancers, with clinical trials planned at McGill University.

Sunshine Biopharma (NASDAQ:SBFM) has successfully completed an $8 million private placement with the assistance of Aegis Capital Corp. as the exclusive placement agent. This funding will support the development of SBFM-PL4, a potential treatment for COVID-19, which has shown promise in preliminary tests against the virus. In addition to COVID-19 research, Sunshine Biopharma is developing Adva-27a, an anticancer compound effective against multidrug-resistant cancer cells. Clinical trials for Adva-27a in treating pancreatic cancer are planned at McGill University.

Sunshine Biopharma (NASDAQ: SBFM, SBFMW) announced the completion of a private placement, raising approximately $8 million. The company issued 2,301,353 shares of Common Stock with investor warrants and 1,302,251 pre-funded warrants. Each share with investor warrants was sold at $2.22, while pre-funded warrants were sold at $2.219. The exercise price for investor warrants is $2.22, expiring in five years. Sunshine Biopharma is advancing oncology and antiviral drug development, including potential COVID-19 treatments and the anticancer compound Adva-27a.

Sunshine Biopharma, Inc. (SBFM, SBFMW) announced a securities purchase agreement generating approximately $8.0 million from institutional and accredited investors. The offering involves 3,603,604 units priced at $2.22 each, with each unit consisting of a share of common stock and a non-tradable warrant. The closing is expected around March 14, 2022. Sunshine Biopharma is developing treatments for COVID-19 and various cancers, including its lead compound SBFM-PL4 and anticancer drug Adva-27a, with clinical trials planned in collaboration with prestigious institutions.